MedTrace Logo

CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

NCT00044018 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2019-11-12

No results posted yet for this study

Summary

The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.

Conditions

Interventions

DRUG

CDC-501

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Robert Knight, MD · Celgene Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-01
Primary Completion
2004-12-01
Completion
2007-02-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00044018 on ClinicalTrials.gov